In vitro activity of Penicillium chrysogenum antifungal protein (PAF) and its combination with fluconazole against different dermatophytes

Department of Microbiology, Faculty of Science and Informatics, University of Szeged, Közép fasor 52., Szeged, Hungary.
Antonie van Leeuwenhoek (Impact Factor: 1.81). 07/2008; 94(3):463-70. DOI: 10.1007/s10482-008-9263-x
Source: PubMed


Strains of five dermatophyte species (Microsporum canis, Microsporum gypseum, Trichophyton mentagrophytes, Trichophyton rubrum and Trichophyton tonsurans) were selected for testing against Penicillium chrysogenum antifungal protein (PAF) and its combination with fluconazole (FCZ). Inhibition of microconidia germination and growth was detected with MICs of PAF ranging from 1.56 to 200 microg ml(-1) when it was used alone, or at constant concentration (100 microg ml(-1)) in combination with FCZ at from 0.25 to 32 microg ml(-1). The MICs for FCZ were found to be between 0.25 and 128 microg ml(-1). PAF caused a fungicidal effect at 200 microg ml(-1) and reduced growth at between 50 and 200 microg ml(-1). Total growth inhibition with fungistatic activity was detected at 64 microg ml(-1) of FCZ for M. gypseum, T. mentagrophytes, and T. tonsurans, and at 32 microg ml(-1) FCZ for M. canis and T. rubrum. PAF and FCZ acted synergistically and/or additively on all of the tested fungi except M. gypseum, where no interactions were detected.

Download full-text


Available from: Laszlo Galgoczy, Apr 17, 2015
  • Source
    • "Aala and collaborators [41] found good activity between allicin in combination with ketoconazole or fluconazole demonstrating a synergistic or additive interaction against dermatophytes. Galgóczy and coauthors [42] evaluated the in vitro antifungal activity against strains of dermatophytes, combining the protein (PAF) of Penicillium chrysogenum with fluconazole (FCZ). PAF and FCZ acted synergistically and/or additively on all of the tested fungi except Microsporum gypseum, for which no interactions were detected [42]. "
    [Show abstract] [Hide abstract]
    ABSTRACT: Dermatophytosis and superficial mycosis are a major global public health problem that affects 20–25% of the world’s population. The increase in fungal resistance to the commercially available antifungal agents, in conjunction with the limited spectrum of action of such drugs, emphasises the need to develop new antifungal agents. Natural products are attractive prototypes for antifungal agents due to their broad spectrum of biological activities. This study aimed to verify the antifungal activity of protocatechuic acid, 3,4-diacetoxybenzoic, and fourteen alkyl protocatechuates (3,4-dihydroxybenzoates) against Trichophyton rubrum and Trichophyton mentagrophytes and to further assess their activities when combined with fluconazole. Susceptibility and synergism assays were conducted as described in M38-A2 (CLSI), with modifications. Three strains of Trichophyton rubrum and three strains of Trichophyton mentagrophytes were used in this work. The pentyl, hexyl, heptyl, octyl, nonyl, and decyl protocatechuates showed great fungicidal effects, with minimum inhibitory concentration (MIC) values ranging from 0.97 to 7.8 mg/L. Heptyl showed a synergistic activity (FIC index = 0.49 ), reducing the MIC of fluconazole by fourfold. All substances tested were safe, especially the hexyl, heptyl, octyl, and nonyl compounds, all of which showed a high selectivity index, particularly in combination with fluconazole. These ester associations with fluconazole may represent a promising source of prototypes in the search for anti-Trichophyton therapeutic agents.
    Full-text · Article · Jun 2014 · Evidence-based Complementary and Alternative Medicine
  • Source
    • "The extracellular, defensin-like antifungal proteins secreted by filamentous ascomycetes are interesting in this respect both in medicine and agriculture . These proteins have potent antifungal activity against potential human, plant and food-borne pathogenic fungal species [1] [2] [3], they could not have any toxic effects on plant and mammalian cells in vitro and in vivo [2] [4] [5], they can interact synergistically with other antifungal drugs and peptides [6] [7] [8], and they have high stability against protease degradation, high temperature and that they are active within broad pH range [1]. These facts and their low costs of production could make them promising candidates as a base of commercial biopesticides, medicines and food preservatives against harmful filamentous fungi [1] [2]. "
    [Show abstract] [Hide abstract]
    ABSTRACT: Neosartorya fischeri NRRL 181 isolate secretes a defensin-like antifungal protein (NFAP) which has a remarkable antifungal effect against ascomycetous filamentous fungi. This protein is a promising antifungal agent of biotechnological value; however in spite of the available knowledge of the nature of its 5′-upstream transcriptional regulation elements, the bulk production of NFAP has not been resolved yet. In this study we carried out its heterologous expression in the yeast Pichia pastoris and investigated the growth inhibition effect exerted by the heterologous NFAP (hNFAP) on filamentous fungal isolates from human infections compared with what was caused by the native NFAP. P. pastoris KM71H transformant strain harboring the pPICZαA plasmid with the mature NFAP encoding gene produced the protein. The final yield of the hNFAP was sixfold compared to the NFAP produced by N. fischeri NRRL 181. Based on the signal dispersion of the amide region, it was proven that the hNFAP exists in folded state. The purified hNFAP effectively inhibited the growth of fungal isolates belonging to the Aspergillus and to the Fusarium genus, but all investigated zygomycetous strain proved to be insusceptible. There was no significant difference between the growth inhibition effect exerted by the native and the heterologous NFAP. These data indicated that P. pastoris KM71H can produce the NFAP in an antifungally active folded state. Our results provide a base for further research, e.g., investigation the connection between the protein structure and the antifungal activity using site directed mutagenesis.
    Full-text · Article · Nov 2013 · Protein Expression and Purification
  • Source
    • "PAF is a low molecular weight (6.5 kD), basic, and cysteine-rich protein whose N-terminal amino acid sequence (GenBank accession number AAA92718) has a homology with other antifungal proteins produced by other fungi (Marx et al., 1995). PAF inhibits the growth of various pathogen fungi including Aspergillus fumigatus, Aspergillus nidulans, Aspergillus niger, Botrytis cinerea (Kaiserer et al., 2003) and some dermatophyte species (Galgoczy et al., 2008). It causes an increased production of reactive oxygen radicals, reduces the metabolism of the fungal cells, and initiates an increased potassium efflux (Kaiserer et al., 2003). "
    [Show abstract] [Hide abstract]
    ABSTRACT: The antifungal protein of Penicillium chrysogenum (PAF) inhibits the growth of important pathogenic filamentous fungi, including members of the Aspergillus family and some dermatophytes. Furthermore, PAF was proven to have no toxic effects on mammalian cells in vitro. To prove that PAF could be safely used in therapy, experiments were carried out to investigate its in vivo effects. Adult mice were inoculated with PAF intranasally in different concentrations, up to 2700μg•kg-1 daily, for two weeks. Even at the highest concentration - a concentration highly toxic in vitro for all affected molds - used, animals neither died due to the treatment nor were any side effects observed. Histological examinations did not find pathological reactions in the liver, in the kidney, and in the lungs. Mass spectrometry confirmed that measurable amount of PAF is accumulated in the lungs after the treatment. Lung tissue extracts from PAF treated mice exerted significant antifungal activity. Small-animal positron emission tomography revealed that neither the application of physiological saline nor that of PAF induced any inflammation while the positive control lipopolysaccharide did. The effect of the drug on the skin was examined in an irritative dermatitis model where the change in the thickness of the ears following PAF application was found to be the same as in control and significantly less than when treated with phorbol-12-myristate-13-acetate used as positive control. Since no toxic effects of PAF were found in intranasal application, our result is the first step for introducing PAF as potential antifungal drug in therapy.
    Full-text · Article · Mar 2013 · Toxicology and Applied Pharmacology
Show more